( May 29, 2018, 1:39 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on May 29 denied review of the dismissal of a false claims/kickback lawsuit alleging off-labeling marketing of the antipsychotic drug Abilify (United States of America, ex rel. Joseph Ibanez, et al. v. Bristol-Myers Squibb Company, et al., No. 17-1399, U.S. Sup.)....